T5095C

# **General Information**

| **Position** | **5095** | **Variant** | **m.5095T\>C** | **Locus** | **MT\-ND2** | **Amino\-AcidChange** | **I209T** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Homoplasmy** | nr | **Heteroplasmy** | nr | **APOGEE2** | Likely\-benign | **Pathogenicity** | Reported |

"Pathogenicity" status is derived from published literature or predictions from bioinformatics tools. Researchers and clinicians are cautioned that additional data and/or analysis may still be necessary to confirm the pathological significance of these variants. For more information, please see [Mitofam Info](https://mitofam.com/doc/385/).

# **Pedigree Information**

The **m.5095T\>C** variant in MT\-ND2 has been reported in 1 pedigree. To date, 1 carrier has been reported. Mutation\-load data were not available. The main clinical manifestations among affected carriers included proximal muscle weakness and atrophy, inflammatory muscle histology, large psoriasis\-type rash, myalgia, and orbicularis oculi weakness.

| **No.** | **Position** | **Variant** | **Family ID** | **Nationality** | **Diseases** | **Unaffected Maternal Relatives** | **Affected Maternal Relatives** | **Publication Year** | **PMID/Ref** | **Note** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | 5095 | m.5095T\>C | T5095C\-F1 | Finland | Proximal muscle weakness and atrophy | ND | ND | 2017 | [28187756](https://pubmed.ncbi.nlm.nih.gov/28187756/) |  |

# **Carrier Information**

| **No.** | **Position** | **Variant** | **Family ID** | **Carrier ID** | **Type (Fam/De novo/Uninf)** | **Gender (F/M)** | **Proband (Y/N)** | **Affected (Y/N)** | **Die/Alive(D/A)** | **Age** | **Blood Mutant Level** | **Muscle Mutant level** | **Urine Mutant level** | **Other Mutant level** | **Clinical Features** | **Note** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | 5095 | m.5095T\>C | T5095C\-F1 | T5095C\-F1\-P1 | Uninf | ND | Y | Y | ND | ND | / | / | / | / | Proximal muscle weakness and atrophy, orbicularis oculi weakness, myalgia, large psoriasis\-type rash, inflammatory muscle histology |  |

For abbreviations and other usage instructions, please see [Mitofam Info](https://mitofam.com/doc/385/).